CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Celldex Therapeutics has not reported a dividend
No dividend per share appears in Celldex Therapeutics's annual filings since fiscal 2010.